Core Viewpoint - The company expects a significant increase in profit for the fiscal year ending December 31, 2025, projecting a profit between approximately $88 million (around HKD 685 million) and $95 million (around HKD 739 million), compared to a profit of about $2.7 million for the fiscal year ending December 31, 2024 [1] Financial Projections - The anticipated adjusted profit totals are expected to range from $91 million (approximately HKD 708 million) to $98 million (approximately HKD 763 million) [1] - The expected profit increase is primarily attributed to the continuous growth of the company's recurring revenue [1] Revenue Drivers - Recurring revenue growth is driven by ongoing research collaborations with partners such as AstraZeneca and Bristol-Myers Squibb [1] - The global partnership network is expanding, with revenue from innovative product licensing and collaborations becoming a significant source of recurring income, including licensing agreements with Otsuka Pharmaceutical and Windward Bio [1] - Rapid growth in the business of Nona Bio is noted, including revenue from technology licensing and platform-based services, as well as milestone payments from existing collaborations, such as research and technology licensing agreements with Pfizer [1]

Core Viewpoint - The company expects a significant increase in profit for the fiscal year ending December 31, 2025, projecting a profit between approximately $88 million (around HKD 685 million) and $95 million (around HKD 739 million), compared to a profit of about $2.7 million for the fiscal year ending December 31, 2024 [1] Group 1: Profit Projections - Expected profit for the fiscal year ending December 31, 2025, is projected to be between $88 million and $95 million [1] - For the fiscal year ending December 31, 2024, the expected profit is approximately $2.7 million [1] - Adjusted total profit is anticipated to be between $91 million (approximately HKD 708 million) and $98 million (approximately HKD 763 million) [1] Group 2: Revenue Growth Drivers - The increase in expected profit is primarily attributed to the continuous growth of the company's recurring revenue [1] - Collaborations with AstraZeneca and Bristol-Myers Squibb are contributing to the recurring revenue through platform-based research partnerships [1] - The global partner network is expanding, leading to revenue from licensing and collaborations, such as partnerships with Otsuka Pharmaceutical and Windward Bio [1] Group 3: Business Expansion - The rapid growth of Nona Bio's business is contributing to revenue through technology licensing and platform-based services [1] - Revenue from milestone payments from existing collaborations, including research and technology licensing with Pfizer, is also a significant factor [1]

Core Viewpoint - The company, Heptares Therapeutics, expects a significant increase in profits for the fiscal year ending December 31, 2025, projecting a profit between approximately $88 million and $95 million, compared to a modest profit of about $2.7 million for the fiscal year ending December 31, 2024 [1] Financial Projections - The anticipated profit for the fiscal year ending December 31, 2025, is estimated to be between $88 million (approximately HKD 685 million) and $95 million (approximately HKD 739 million) [1] - For the fiscal year ending December 31, 2024, the expected profit is around $2.7 million [1] - The adjusted total profit is projected to be between $91 million (approximately HKD 708 million) and $98 million (approximately HKD 763 million) [1]

Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142.HK), anticipates a significant increase in profit for the fiscal year ending December 31, 2025, projecting earnings between approximately $88 million (around HKD 685 million) and $95 million (around HKD 739 million), compared to an estimated profit of about $2.7 million for the fiscal year ending December 31, 2024 [1] Group 1 - The expected increase in profit is primarily attributed to the continuous growth of the company's recurring revenue [1] - The company has expanded its global partnership network, which has accelerated due to revenue generated from licensing and collaboration on innovative products [1] - Notable collaborations include partnerships with AstraZeneca, Bristol-Myers Squibb, Otsuka Pharmaceutical, and Windward Bio, contributing to the recurring revenue stream [1] Group 2 - The rapid growth of the business segment related to Nona Bio is highlighted, including revenue from technology licensing and platform-based services [1] - Milestone payments from existing collaborations, such as research and technology licensing agreements with Pfizer, are also contributing to revenue growth [1]

和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） 附註： 1. 溢利調整項目為員工持股計劃相關費用。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：02142） 正面盈利警告 本公告乃由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）遵 照香港聯合交易所有限公司《證券上市規則》（「上市規則」）第13.09條及證券及期 貨條例（「證券及期貨條例」）（香港法例第571章）第XIVA部的規定而作出。 本公司董事（「董事」）會（「董事會」）欣然知會本公司股東（「股東」）及潛在投資 者，根據對本集團截至2025年12月31日止年度未經審計管理賬目之初步審閱，預 期截至2025年12月31日止年度的溢利介乎約88百萬美元（相當於約685百萬港元） 至約95百萬美元（相當於約739百萬港元），而截至2024年12月31日止年度則為 溢利約2.7百萬美元。預期經調整溢利總額1介乎91百萬美 ...

热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 和铂医药-B（02142）早盘股价上涨3.61%，现报12.34港元，成交额3099.05万港元。 和铂医药-B（02142）早盘股价上涨3.61%，现报12.34港元，成交额3099.05万港元。 1月29日，和铂医药-B发布公告，根据公司股东于公司2025年6月11日举行的股东周年大会上批准的购回 股份的一般授权及（如适用）未来股东于公司不时的股东大会上批准的购回股份的任何一般授权，其拟 不时于公开市场上购回价值不超过3亿港元的公司股份。 值得关注的是，近日，和铂医药-B介绍AI智药业务的最近进展情况。此前，公司曾推出Hu-mAtrIx™人 工智能平台，并在此基础上建立了首个全人源AI HCAb模型——全人源重链抗体（HCAb）生成和筛选 模型。和铂医药-B将AI智药提升到战略意义层面的高度，打造整合抗体工程、AI辅助药物发现、自动 化湿实验室三位一体的A3大分子创新药物研发平台，干湿结合以实现AI智药的真实落地场景，海量湿 实验数据反哺AI模型实现高质量训练的正反馈循环。 ...

智通财经APP获悉，和铂医药-B(02142)涨超3%，截至发稿，涨1.85%，报12.18港元，成交额1403.89万 港元。 值得关注的是，近日，和铂医药-B介绍AI智药业务的最近进展情况。此前，公司曾推出Hu-mAtrIx™人 工智能平台，并在此基础上建立了首个全人源AI HCAb模型——全人源重链抗体(HCAb)生成和筛选模 型。和铂医药-B将AI智药提升到战略意义层面的高度，打造整合抗体工程、AI辅助药物发现、自动化 湿实验室三位一体的A3大分子创新药物研发平台，干湿结合以实现AI智药的真实落地场景，海量湿实 验数据反哺AI模型实现高质量训练的正反馈循环。 消息面上，1月29日，和铂医药-B发布公告，根据公司股东于公司2025年6月11日举行的股东周年大会上 批准的购回股份的一般授权及(如适用)未来股东于公司不时的股东大会上批准的购回股份的任何一般授 权，其拟不时于公开市场上购回价值不超过3亿港元的公司股份。 ...

值得关注的是，近日，和铂医药-B介绍AI智药业务的最近进展情况。此前，公司曾推出Hu-mAtrIx人工 智能平台，并在此基础上建立了首个全人源AI HCAb模型——全人源重链抗体(HCAb)生成和筛选模 型。和铂医药-B将AI智药提升到战略意义层面的高度，打造整合抗体工程、AI辅助药物发现、自动化 湿实验室三位一体的A3大分子创新药物研发平台，干湿结合以实现AI智药的真实落地场景，海量湿实 验数据反哺AI模型实现高质量训练的正反馈循环。 消息面上，1月29日，和铂医药-B发布公告，根据公司股东于公司2025年6月11日举行的股东周年大会上 批准的购回股份的一般授权及(如适用)未来股东于公司不时的股东大会上批准的购回股份的任何一般授 权，其拟不时于公开市场上购回价值不超过3亿港元的公司股份。 和铂医药-B(02142)涨超3%，截至发稿，涨1.85%，报12.18港元，成交额1403.89万港元。 ...

和铂医药-B(02142)发布公告，根据公司股东于公司2025年6月11日举行的股东周年大会上批准的购回股 份的一般授权及(如适用)未来股东于公司不时的股东大会上批准的购回股份的任何一般授权，其拟不时 于公开市场上购回价值不超过3亿港元的公司股份。 ...

智通财经APP讯，和铂医药-B(02142)发布公告，根据公司股东于公司2025年6月11日举行的股东周年大 会上批准的购回股份的一般授权及(如适用)未来股东于公司不时的股东大会上批准的购回股份的任何一 般授权，其拟不时于公开市场上购回价值不超过3亿港元的公司股份。 ...